Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials.
The therapeutic misconception arises wherever human subjects misinterpret the primary purpose of a clinical trial as therapeutic. Such misconceptions are particularly prevalent in trials involving severely ill subjects or novel and well-publicized investigational agents. In order to identify possible sources of the therapeutic misconception in gene transfer trials, 286 phase 1 human gene transfer consent documents were analyzed for their description of purpose, alternatives, and their use of the term gene transfer. We report that 20% of trials fail to explain their purpose as safety and dosage, only 41% of oncology trials identify comfort care as an alternative to participation, and that the term gene therapy is used with twice the frequency of the term gene transfer. Trends and coherence in consent form language were analyzed as well. Our results indicate that consent forms used in gene transfer phase 1 trials often contain language that promotes, or does little to deter, therapeutic misconceptions.
Kimmelman
Jonathan
J
Clinical Trials Research Group, Biomedical Ethics Unit/Faculty of Medicine, McGill University, Montreal, Quebec H3A 1X1, Canada. jonathan.kimmelman@mcgill.ca
Levenstadt
Aaron
A
D017321:Clinical Trials, Phase I as Topic; D032962:Consent Forms; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods* / Q000523:psychology; D006801:Humans; D008495:Medical Oncology; D010342:Patient Acceptance of Health Care; D035844:Researcher-Subject Relations; D009626:Terminology as Topic